Hans Schambye

Galec­to reaps $64M to bring lead drug across IPF fin­ish line, while mak­ing moves in NASH and be­yond

Back in 2018, Hans Scham­bye raised $90 mil­lion to kick off a late-stage tri­al that could put Galec­to Biotech’s lead drug on the fi­nal stretch to­ward ap­proval for id­io­path­ic pul­monary fi­bro­sis. Two years lat­er, he’s col­lect­ed an­oth­er $64 mil­lion to com­plete it.

The Copen­hagen-based com­pa­ny has man­aged to con­tin­ue re­cruit­ment for the 450-pa­tient tri­al in spite of the pan­dem­ic, the CEO told End­points News, with da­ta ex­pect­ed by the mid­dle of 2022.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.